Tagworks Pharmaceuticals, gevestigd in het Radboudumc, heeft een nieuwe techniek ontwikkeld om chemotherapie gericht af te geven bij tumoren waarbij dat tot dusver heel moeilijk bleek. Door de chemo gecontroleerd los te...
8 psychologische onderzoeken & de inzichten voor je marketingteam
De economie gaat uit van een rationeel denkende consument. Maar de laatste decennia hebben ons voldoende inzichten gegeven dat consumenten lang niet altijd rationeel handelen.
Novartis says Kymriah receives second FDA approval
Swiss drugmaker Novartis said it received a second approval from the U.S. Food and Drug Administration (FDA) for a second form of the blood cancer drug Kymriah.
United Therapeutics to acquire SteadyMed for $216 million
United Therapeutics is set to acquire speciality pharma firm SteadyMed after it emerged that the pair had signed a definitive merger agreement.
Novartis reveals more data for Eylea rival
Building on the back of strong data released at the end of last year, Novartis has released further positive Phase 3 data on its treatment for neovascular age-related macular degeneration (nAMD), brolucizumab.
Ovarian cancer rates set to rise by 55%
Ahead of World Ovarian Cancer Day on 8 May, new figures have been released suggesting that rates of this type of cancer are set to greatly increase globally by nearly 55% over the next 20 years.
Lilly hires new leader of immuno-oncology
Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping massive annual sales.
Medix neemt E-wise Medical over
Medix Publishers heeft E-WISE Medical overgenomen. Hierdoor verstevigt Medix zijn huidige marktpositie als medische uitgeverij en kan Medix de dienstverlening aan zowel zijn eigen klanten als de klanten van E-WISE...
Allergan unveils second bout of Phase 3 success in migraine
Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, showing that the drug met its primary endpoint in the...
Social media: 10 tips voor meer engagement
Of je recent gestart bent met het inzetten van social media of al jaren actief bent, het ontwikkelen van content blijft een uitdaging. Waarover ga je posten? Wat vindt je doelgroep interessant? En wat is voor je...
FDA moots a return look at Acadia’s lead drug
Following a non-profit report that higher rates of death were associated with Acadia Pharmaceuticals’ Nuplazid, Scott Gottlieb has made comments suggesting the FDA may return to take a second look at the drug.
Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care
EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible for the development of programmes to combat the prominent health threat...
Vertex Pharma profit tops estimates on strong launch of new CF drug
Vertex Pharmaceuticals Inc topped analysts’ forecasts for quarterly profit, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.
Abbvie’s beat fueled by demand for Humira, Hep C drugs
Abbvie reported a better-than-expected quarterly profit, driven by higher sales of its rheumatoid arthritis treatment Humira and its Hepatitis C drugs, leading the company to raise its full-year earnings forecast.
Mobile First: in 2018 moet je voorop lopen
Marketeers kunnen het beamen: het grootste aandeel aan internetverkeer is vandaag de dag afkomstig van een mobiel apparaat. Hier heb je vast al op ingespeeld met een responsive webdesign, maar wist je dat je nog een...
Takeda strikes deal to buy Shire for £46bn
Japanese company makes its biggest bet to join the top ranks of global pharma groups.
AstraZeneca third-line lung cancer combination study fails
A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping patients live...
Novartis forges forward into digital pharma with FocalView app
There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and Novartis is one of the companies that is most actively announcing steps to explore this possibility.



![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)




